Skip to main content
. 2014 Sep 25;9:109. doi: 10.1186/s13012-014-0109-9

Table 4.

Characteristics of patients who completed the risk assessment questionnaire (n = 351)*

Characteristics Site 1 Site 2 Site 3 Combined Sites P value
Between sites Between women and men
No. (%) of patients 110 (21) 124 (21) 117 (11) 351 (16) NA
Women 81 (74) 93 (75) 98 (84) 272 (77) 0.13 NA
Men 29 (26) 31 (25) 19 (16) 79 (23)
Age, mean (SD), y 64 (9.56) 64 (10.40) 64 (10.55) 64 (10.2) 0.88 <0.001
Age range, y 50-87 50-90 50-89 50-90 NA
Time to complete RAQ, mean (SD), min 3.26 (1.05) 3.42 (1.29) 3.60 (1.28) 3.43 0.08 0.37
Range of completion time, mean, min 1.32-7.93 1.37-8.01 1.37-7.38 1.32-8.01 NA
Number of visits, mean (SD) 3.29 (1.95) 2.37 (1.85) 3.25 (3.14) 2.95 (2.4) 0.004 0.88
Range§ 0-10 0-9 0-25 0-25 NA
Number (%) of patients who had a BMD test
Over 2 y ago 39 (35) 38 (31) 24 (21) 101 (29) 0.03 <0.001
Less than 2 y ago 38 (35) 30 (24) 35 (30) 103 (29) 0.22 0.005
Never 33 (30) 56 (45) 58 (50) 147 (42) 0.008 <0.001
Number (%) of patients at risk for osteoporosis 88 (80) 97 (78) 91 (78) 276 (79) 0.91 <0.001
Number (%) of patients already receiving therapy
Osteoporosis medications 8 (7) 13 (10) 11 (9) 32 (9) 0.69 0.02
Any supplement (calcium or vitamin D) 71 (65) 81 (65) 81 (69) 233 (66) 0.72 <0.001

*All data based on Risk Assessment Questionnaire (RAQ) inputs; SD = standard deviation; BMD = bone mineral density; NA = not applicable.

Based on analysis of variance or chi-square tests.

Percentage calculated as the number of age-eligible patients who completed the RAQ divided by the number of age-eligible patients with at least 1 physician visit. All percentages in subsequent rows calculated with respect to the number of age-eligible patients who completed the RAQ at the particular site.

§The lower limit of the range is 0 because some patients completed the RAQ during a ‘non-visit’ (i.e., visited the practice but did not see a physician or nurse).

At-risk for osteoporosis is defined as 1 major or 2 minor risk factors according to clinical practice guidelines [30].